+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 67 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.

Age: 18Years - 80YearsAll GendersPhase 2
107 locations
E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations
E

Actively Recruiting

Researchers are evaluating a new treatment called MK-8748 for people with diabetic macular edema DME, a condition that can cause vision loss in people with diabetes. This trial compares MK-8748 to an existing standard treatment called aflibercept to see if MK-8748 works as well. The study is a randomized, double-masked, pivotal phase 3 trial focusing on treatment safety and effectiveness. Participants are assigned to one of three groups a low dose of MK-8748, a high dose of MK-8748, or the standard aflibercept treatment. Those receiving MK-8748 will get five initial injections every 4 weeks, then continue every 8 weeks until week 48, followed by personalized treatment intervals up to week 100. Participants in the aflibercept group receive injections every 4 weeks for five doses, then every 8 weeks up to week 100. During the study, participants will have regular eye exams and vision tests to measure changes in visual acuity and eye thickness. Researchers will monitor how well treatments reduce retinal swelling and improve diabetic retinopathy severity using imaging and questionnaires. Safety will be closely observed, including adverse events and antibody levels, over approximately two years. The main focus is to assess the change in best-corrected visual acuity from baseline to one year.

Age: 18Years +All GendersPhase 3
20 locations
E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, immune response, and pharmacokinetics of UGN-501, a chimeric oncolytic adenovirus, given directly into the bladder for adults with recurrent non-muscle invasive bladder cancer NMIBC. This Phase 1, open-label, dose-escalation study focuses on participants with high-grade and low-grade Ta andor T1 disease or carcinoma in situ CIS, aiming to find the recommended dose for further study. Participants will undergo a 12-week Induction Period with six weekly intravesical instillations of UGN-501. Those with certain disease types who respond or do not have recurrence will continue into a Maintenance Period, receiving three weekly instillations every three months from Month 3 to Month 12. Disease assessments occur every three months up to 15 months or until recurrence, progression, or death. The study may add other intervention arms or dose expansions in future amendments. During the study, participants will have regular evaluations including monitoring for dose-limiting toxicities, adverse events, drug levels in blood and urine, and immune response. Disease status will be assessed at specified intervals, with follow-up lasting up to 15 months. The main outcomes measured include safety, complete response rate at 3 months, and recurrence-free survival at 6 months, along with detailed pharmacokinetic and viral shedding analyses.

Age: 18Years +All GendersPhase 1
15 locations
P

Actively Recruiting

Researchers are studying UGN-104, a new form of UGN-101 also known as JELMYTO, to evaluate its safety and effectiveness for treating low-grade upper tract urothelial cancer LG-UTUC. This phase 3 study focuses on patients with this type of cancer located in the upper urinary tract. The research aims to understand how well UGN-104 works when placed directly into the affected area and to monitor its safety during treatment. Participants will receive UGN-104 once a week for six weeks, totaling six doses. This medication combines mitomycin with a special gel that becomes semi-solid at body temperature, allowing it to stay in the urinary tract longer. After about three months from the first dose, patients undergo evaluation to check for complete response, which includes urine tests and visual exams of the urinary tract. Those who respond completely may receive monthly maintenance doses of UGN-104 for up to 11 months. Patients who do not respond fully complete the study at this point. Throughout the study, participants will have regular clinic visits every three months for up to a year after their initial evaluation or until the cancer returns, worsens, or the patient passes away. Assessments include urine cytology, ureteroscopy, biopsies if needed, and laboratory tests to monitor mitomycin levels and side effects. Researchers will track treatment response duration, safety events, and drug concentrations to better understand the therapy and its effects over time.

Age: 18Years +All GendersPhase 3
79 locations
L

Actively Recruiting

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Age: 18Years - 50YearsFEMALEPhase 3
120 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
91 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efimosfermin alfa in adults with compensated cirrhosis caused by Metabolic Dysfunction-associated Steatohepatitis MASH. This phase 3 clinical trial compares efimosfermin alfa with a placebo to better understand its impact on liver-related clinical outcomes in this population. Participants will be randomly assigned to receive either efimosfermin alfa or a placebo through subcutaneous injections. The study is designed with two groups and uses a quadruple-blind method to ensure unbiased results. Treatment and follow-up occur over a long period, with key assessments at baseline, Week 96, Week 260, and Week 356. During the trial, participants will undergo various evaluations including liver stiffness measurements, fibrosis scores, laboratory tests, and patient-reported questionnaires related to fatigue and liver disease quality of life. Researchers will monitor safety through adverse event reporting and lab abnormalities. The primary outcome is the time to a liver-related clinical event, observed from the start of treatment up to Week 356, providing comprehensive long-term data on treatment effects.

Age: 18Years - 75YearsAll GendersPhase 3
15 locations

1-10 of 67

1